In this work, we interrogate how PGS for T2D (including five partitioned T2D scores13: beta cell, lipodystrophy, liver lipid, obesity, proinsulin) and its cardiometabolic complications (coronary artery disease - CAD, chronic kidney disease - CKD and adiposity ascertained as body mass index - BMI) perturb the plasma proteome using data from the UK Biobank Pharma Proteomics Project (UKB-PPP)16,17. This evidence concerns the gene INS and type 2 diabetes mellitus.